By unraveling the molecular mechanisms of β‐catenin translocation from plasma membrane to the nucleus and E‐cadherin relocalization at the cell membrane, in accordance with UBE2T expression levels, we could identify novel potential therapeutic strategies in HCC. Here, UBE2T is linked to hepatocellular carcinoma.